239 related articles for article (PubMed ID: 19208096)
1. Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids.
Musolino A; Panebianco M; Zendri E; Santini M; Di Nuzzo S; Ardizzoni A
Br J Haematol; 2009 Apr; 145(1):84-6. PubMed ID: 19208096
[TBL] [Abstract][Full Text] [Related]
2. Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma.
Cabello I; Servitje O; Corbella X; Bardés I; Pintó X
Clin Exp Dermatol; 2017 Apr; 42(3):276-281. PubMed ID: 28233333
[TBL] [Abstract][Full Text] [Related]
3. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
Assaf C; Bagot M; Dummer R; Duvic M; Gniadecki R; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2006 Aug; 155(2):261-6. PubMed ID: 16882161
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
[TBL] [Abstract][Full Text] [Related]
5. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Scarisbrick JJ; Morris S; Azurdia R; Illidge T; Parry E; Graham-Brown R; Cowan R; Gallop-Evans E; Wachsmuth R; Eagle M; Wierzbicki AS; Soran H; Whittaker S; Wain EM
Br J Dermatol; 2013 Jan; 168(1):192-200. PubMed ID: 22963233
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
7. The optimal use of bexarotene in cutaneous T-cell lymphoma.
Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
[TBL] [Abstract][Full Text] [Related]
8. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.
Väkevä L; Ranki A; Hahtola S
Acta Derm Venereol; 2012 May; 92(3):258-63. PubMed ID: 22678563
[TBL] [Abstract][Full Text] [Related]
9. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma.
Ballanger F; Nguyen JM; Khammari A; Dréno B
Dermatology; 2010; 220(4):370-5. PubMed ID: 20484880
[TBL] [Abstract][Full Text] [Related]
10. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
11. Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas.
Martin AG
J Drugs Dermatol; 2003 Apr; 2(2):155-67. PubMed ID: 12852367
[TBL] [Abstract][Full Text] [Related]
12. Combination treatment modalities in cutaneous T-cell lymphoma (CTCL).
Guitart J
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S17-20. PubMed ID: 16516671
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.
Singh F; Lebwohl MG
J Am Acad Dermatol; 2004 Oct; 51(4):570-3. PubMed ID: 15389192
[TBL] [Abstract][Full Text] [Related]
14. Bexarotene: a clinical review.
Farol LT; Hymes KB
Expert Rev Anticancer Ther; 2004 Apr; 4(2):180-8. PubMed ID: 15056048
[TBL] [Abstract][Full Text] [Related]
15. About the cutaneous targets of bexarotene in CTCL patients.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e299-301. PubMed ID: 19845753
[TBL] [Abstract][Full Text] [Related]
16. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
Stern DK; Lebwohl M
J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
[TBL] [Abstract][Full Text] [Related]
17. Topical and oral bexarotene.
Schadt CR
Dermatol Ther; 2013; 26(5):400-3. PubMed ID: 24099070
[TBL] [Abstract][Full Text] [Related]
18. Bexarotene: new preparation. Cutaneous lymphoma: too many adverse effects.
Prescrire Int; 2004 Jun; 13(71):94-7. PubMed ID: 15233146
[TBL] [Abstract][Full Text] [Related]
19. CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.
Gopaluni S; Perzova R; Abbott L; Farah R; Shrimpton A; Hutchison R; Poiesz BJ
Am J Hematol; 2008 Sep; 83(9):744-6. PubMed ID: 18615708
[TBL] [Abstract][Full Text] [Related]
20. Bexarotene (Targretin) for cutaneous T-cell lymphoma.
Med Lett Drugs Ther; 2000 Apr; 42(1075):31-2. PubMed ID: 10788961
[No Abstract] [Full Text] [Related]
[Next] [New Search]
